Infinity Pharmaceuticals (NASDAQ:INFI) Receives Media Impact Score of 0.31

Share on StockTwits

News articles about Infinity Pharmaceuticals (NASDAQ:INFI) have been trending positive recently, according to Accern. The research firm scores the sentiment of news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Infinity Pharmaceuticals earned a news sentiment score of 0.31 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 46.8493119379919 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Infinity Pharmaceuticals stock traded down $0.10 during mid-day trading on Friday, hitting $1.87. The company had a trading volume of 913,648 shares, compared to its average volume of 746,195. The firm has a market capitalization of $104.44, a P/E ratio of -2.25 and a beta of 2.49. Infinity Pharmaceuticals has a 1 year low of $0.93 and a 1 year high of $3.75.

Infinity Pharmaceuticals (NASDAQ:INFI) last announced its earnings results on Thursday, March 15th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.11. sell-side analysts predict that Infinity Pharmaceuticals will post -0.74 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Infinity Pharmaceuticals (NASDAQ:INFI) Receives Media Impact Score of 0.31” was originally reported by BBNS and is owned by of BBNS. If you are viewing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The correct version of this piece of content can be viewed at https://baseballnewssource.com/2018/04/06/infinity-pharmaceuticals-infi-receives-daily-media-impact-score-of-0-31/2037438.html.

Infinity Pharmaceuticals Company Profile

Infinity Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers.

Insider Buying and Selling by Quarter for Infinity Pharmaceuticals (NASDAQ:INFI)

Receive News & Ratings for Infinity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.